An observational study in Atrial Functional Mitral Regurgitation and Mitral Insufficiency, sponsored by University Hospital of Cologne. Recruiting at 22 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-06.
Sponsored by University Hospital of Cologne · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Mitral Valve Insufficiency with a site in Germany — 24 open to participants now, 32 under way, none of them phase 3. Mitral Valve Insufficiency · Germany.
Among the 81 studies in Mitral Valve Insufficiency with a site in Germany, this one is the 6th largest by planned enrollment of the 33 observational ones that give a count, is the only one that started in 2010, is one of 33 observational ones, reaches primary completion later than 26 of the 31 other live ones, and was the 76th registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →24 of the 81 studies in Mitral Valve Insufficiency with a site in Germany are open now. Recruiting first, the newest first:
University Medical Center Mainz · Sites in Germany
Ages 18+
Jena University Hospital · Sites in Germany
Ages 18+
Medical University of Vienna · Sites in Germany, Austria, Italy and 1 more country
Ages 18+
4C Medical Technologies, Inc. · Sites in Germany, United States, Canada and 4 more countries
Ages 18+
LMU Klinikum · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 4 3
First in 2006; this study’s year is marked. 1 started in 2010.
This study's planned enrollment of 1,000 is above the median of 159 across 170 observational studies indexed under Mitral Valve Insufficiency.
Median enrollment 113 across the 48 interventional studies, 214 across the 33 observational. Of the 37 that completed or were terminated, 12 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 81 have an industry lead sponsor. The 10 most frequent:
University Hospital of Cologne is the lead sponsor of 42 studies on the registry; 15 are open to participants now.
University Hospital of Cologne has 2 studies filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
4 of the studies in Mitral Valve Insufficiency with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04029363HighLife SASExpanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk | 2026-12-15 |
| NCT03339115Cardiovalve Ltd.AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System | 2026-12-31 |
| NCT04898335LMU KlinikumTendyne European Experience Registry | 2026-12-31 |
| NCT06634121LMU KlinikumEfficacy of MitraCLip Vs. PASCAL for the TrEAtment of MitraL REgurgiTation in an All-comer Population | 2027-04-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 81 studies in Mitral Valve Insufficiency with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This investigator-initiated, multicenter, international, retrospective registry aims to investigate outcomes of patients with atrial functional mitral regurgitation, as treated in clinical routine.
This study aimes to include all patients with clinically significant mitral regurgitation of the atrial functional mitral regurgitation subtype, irrespective of the subsequent therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who underwent mitral valve transcatheter edge-to-edge repair. All devices may be included.
Patients who underwent conservative management with guideline directed medical therapy.
Patients who underwent transcatheter mitral valve replacement. All devices may be included.
Composite of all-cause mortality and heart-failure related rehospitalitzation
Time frame: 12 months
Residual Mitral Regurgitation ≤1+
Rate of patients achieving residual mitral regurgitation ≤1+ measured by transthoracic echocardiography. Assessment of mitral regurgitation severity according to current guidelines (ESC/EACTS and ACC/AHA) for valvular heart disease.
Time frame: 12 months
All-cause mortality
Time frame: 12 months
Cardiovascular mortality
Time frame: 12 months
Heart failure related rehospitalization
Incidence of new-onset or worsening signs and symptoms of heart failure that required urgent therapy and resulted in hospitalization.
Time frame: 12 months
Unplanned mitral valve intervention
Incidence of unplanned surgical or transcatheter re-intervention, heart transplantation or left ventricular assist device implantation.
Time frame: 12 months
New York Heart Association (NYHA) class III or IV
Assessment of New York Heart Association (NYHA) classification stage (in- or outpatient), with the minimum of I (no symptoms) and the maximum of IV (dyspnea at rest), with higher values indicating worse functional capacity.
Time frame: 12 months
6 Minute Walking Distance
Time frame: 12 months
Started Jan 2010 (actual). Primary completion is estimated for Dec 2030, 251 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital of Cologne